Literature DB >> 15675135

Clinical manifestations of Behçet's disease in 137 Italian patients: results of a multicenter study.

N Pipitone1, L Boiardi, I Olivieri, F Cantini, F Salvi, R Malatesta, R La Corte, G Triolo, A Ferrante, D Filippini, G Paolazzi, P Sarzi-Puttini, G Restuccia, C Salvarani.   

Abstract

OBJECTIVE: To determine the type and frequency of clinical features of Behçet's disease in a population of Italian patients.
METHODS: We retrospectively studied 137 Italian patients (76 males and 61 females, age at onset 29.6 +/- 12.2 [mean +/- SD] years) seen consecutively in nine different referral centers. The duration of follow-up at study entry was 10.9 +/- 8.2 years. Virtually all patients fulfilled the classification criteria developed by the International Study Group for Behçet's disease. The clinical manifestations of the patients were recorded by the attending physicians using specifically designed forms.
RESULTS: The most frequent manifestations at disease onset were oral (78.3%) and genital aphthae (29.2%) followed by inflammatory ocular involvement (20%) and arthritis (14.2%). The commonest (>50% of cases) manifestations observed throughout the disease course were oral aphthae (99.3%), genital aphthae (62.8%), various cutaneous lesions including erythema nodosum (81.8%), and inflammatory ocular disease (60.6%). Panuveitis and posterior uveitis/retinitis occurred more frequently in males compared with females (28.9% versus 11.5% and 57.9% versus 36.1%, respectively; p < 0.05). 61.6% of our patients were HLA-B51 positive.
CONCLUSION: Behçet's disease in Italian patients is characterized by a variety of clinical manifestations in agreement with the medical literature. Panuveitis and posterior uveitis/retinitis occur more frequently in male patients.

Entities:  

Mesh:

Year:  2004        PMID: 15675135

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  8 in total

1.  Behçet's disease in Brazilian patients: demographic and clinical features.

Authors:  Zoraida Sachetto; Nazira Mahayri; Rosemeire Holanda Ferraz; Lilian Teresa Lavras Costallat; Manoel Barros Bertolo
Journal:  Rheumatol Int       Date:  2011-04-11       Impact factor: 2.631

2.  Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics.

Authors:  Jurgen Sota; Donato Rigante; Giacomo Emmi; Giuseppe Lopalco; Ida Orlando; Gian Marco Tosi; Bruno Frediani; Antonio Vitale; Silvana Guerriero; Florenzo Iannone; Lorenzo Vannozzi; Claudia Fabiani; Luca Cantarini
Journal:  Intern Emerg Med       Date:  2020-02-01       Impact factor: 3.397

3.  The geographic and clinical clusters of Behçet's syndrome.

Authors:  Chiara Marvisi
Journal:  Intern Emerg Med       Date:  2020-03-29       Impact factor: 3.397

4.  Systemic involvements and preferred treatments in a large cohort of Behçet's disease.

Authors:  Sedat Yilmaz; Omer Karadag; Veli Yazisiz; Battal Altun; Mustafa Gezer; Murat Karaman; Muhammet Cinar; Hakan Erdem; Salih Pay; Ayhan Dinc
Journal:  Rheumatol Int       Date:  2013-07-24       Impact factor: 2.631

5.  The natural course and factors affecting severity of Behçet's disease: a single-center cohort of 368 patients.

Authors:  Nilay Ugurlu; Selen Bozkurt; Ali Bacanli; Ayse Akman-Karakas; Soner Uzun; Erkan Alpsoy
Journal:  Rheumatol Int       Date:  2015-06-18       Impact factor: 2.631

6.  Renal amyloidosis in Behçet's disease: clinicopathologic features of 8 cases.

Authors:  Kemal Kosemehmetoglu; Dilek Ertoy Baydar
Journal:  Int Urol Nephrol       Date:  2012-09-09       Impact factor: 2.370

7.  Adamantiades-Behcet disease (ABD) in northern Greece patients: experience from a single center.

Authors:  P Boura; K Tselios; P Skendros; S Kamali; A Sarantopoulos; M Raptopoulou-Gigi
Journal:  Hippokratia       Date:  2007-10       Impact factor: 0.471

8.  Association of MTHFR gene C677T mutation with recurrent aphthous stomatitis and number of oral ulcers.

Authors:  Goknur Kalkan; Nevin Karakus; Serbulent Yigit
Journal:  Clin Oral Investig       Date:  2013-05-11       Impact factor: 3.573

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.